AxoGen, Inc. (AXGN)

[investorpaul]

We sold near $5 in May and rebought our position mid June. I suggested to take profit here and buy back if price stays above the gap. Otherwise we wil buy the gap fill if that happens.

[Prudent Capitalist]

Hope you and your trading group held onto your AXGN and are still in . Lots more room to run for this ticker.

[Prudent Capitalist]

Great news and earnings report out today resulting in surge upward in PPS. Revenue ramping up faster than expected, so lots more room to run. The sky is the limit here with AXGN

[Prudent Capitalist]

Great quarter. Revenue +75% over year ago comparable quarter. AXGN is turning into a cash register!!!! cha Ching!

[Prudent Capitalist]

More like a rocket ship than a roller coaster right now! AXGN still has huge potential here.

[Prudent Capitalist]

From the looks of the current trade and chart, it may not take the full 10 years to reach "Franklinland"

[Prudent Capitalist]

Blew right through that resistance and still surging upward in a big way. Patience has paid off in a big way for longs here, and will reward us even more long term.

[Prudent Capitalist]

Great surge upward here the last couple of days following the strategic investment. AXGN is still very undervalued long term.

[pudbus]

Bull flag setting up key resistance area. http://chartdiligence.com/axgn-bull-flag-setting-up-key-resistance-area/

[Prudent Capitalist]

Like the recent multiple insider buys by the top execs. Lots of promise here. I have a position and am looking to add and build here, and will remain patient, long and strong. Huge potential here with AXGN long term.

[LordTurkeyBaster]

Not much going on here. This will be a $100 stock in 10 years. I can wait...

[running bull]

The chart on AXGN looks like a roller coaster but I like the ride sense I got in. JMO

[LordTurkeyBaster]

Buying

[investorpaul]

Not an alert on ihub but alerted my trading group on my tumblr account back in Sept.

[dog turd cannon]

You alerted it? Interesting.

[investorpaul]

It's been showing signs a long time ago when I alerted it..

[running bull]

AxoGen starting to show some signs of life the last few days. I hope it keeps going.JMO

[btm]

Not many posters here. By the looks of board sometimes a few years go by before a message is left. Doing some D/D here notice a news article from 10/9/12 about PDLI an AXGN it is on this message board listed in the News

[Prudent Capitalist]

Good sign. I have a position in AXGN in a tax deferred account, but it has been a very disappointing investment, as I remain well under water. Acquisition cost was $4.34 per share. Holding long and strong, however.

[btm]

Notice insiders buying

[btm]

To get shareholders talking

[btm]

More Moderators needed

[investorpaul]

I believe it has enough to go to $4 pps. Taking profit isn't bad. Just have to split it up.

[LordTurkeyBaster]

I sold a bit... Too early probably

[Zipp11]

Nice. I still have some shares.

[dog turd cannon]

Up to 3.15...

[investorpaul]

AXGN insiders buying more stocks... Only means one thing.

http://investorpaul.tumblr.com

[Zipp11]

Lol. Nice.

[dog turd cannon]

No... apparently we were not wrong. Man, we need to be wrong sometime.

[Tearex]

Smells like Turkey!

[LordTurkeyBaster]

Hmmmmmm somethings in the oven I think

[LordTurkeyBaster]

We are not

[Zipp11]

Deleted Message.

[Zipp11]

I bought in today. Two of u financial nerds in here can't be wrong.

[investorpaul]

Initiated a solid position today!

http://investorpaul.tumblr.com

[LordTurkeyBaster]

Indeed. I am accumulating

[dog turd cannon]

Boom! (This message has self destructed)

[LordTurkeyBaster]

Thats the spirit. Great day today

[dog turd cannon]

Post.

[LordTurkeyBaster]

Why are there no posts for this outstanding bio?

[Prudent Capitalist]

I took an initial position in AXGN today. Looks very promising to me.

[MissionIR]

We appreciate your comments. Unfortunately, we do not advise people when to enter or exit positions.

[Prudent Capitalist]

Excellent analysis. I am looking seriously at taking a significant position in AXGN, but it seems to go up every day. Have you developed a decent analysis on a favorable entry point?

[Prudent Capitalist]

2013 North American Frost & Sullivan New Product Innovation Leadership Award for developing the Avance® Nerve Graft, a decellularized nerve allograft. Avance® Nerve Graft is the only commercially available processed nerve allograft product available in the United States and is unique because it is free of all the cells and cellular debris from the donor, retaining only the extracellular matrix.

Great stuff. Also:

In conclusion, Equity Options Guru opines his bullish take on the company.

“Based on the 5 reasons above, it appears that AxoGen is headed for a bright future. With the recent insider buying and positive analyst coverage, investors should begin to take notice of this significantly undervalued company. And with the recent improvement in the company’s financials, AxoGen should begin to gain more traction in the nerve repair market and help investors reap the rewards of an early investment,” stated Equity Options Guru

http://seekingalpha.com/article/1724602

[Prudent Capitalist]

Looks very promising. Continuing my DD here, and looking at a substantial investment.

[hedge_fun]

My bride, whom I adore, has a medical degree.....

She saw the segment on Fox and Friends and they had an Iraq war vet that had a procedure don't using the tech. She was impressed.

The stock was at $3.60 when it aired last week.

[Prudent Capitalist]

Very interesting investment opportunity. Doing some DD here, and contemplating an investment. Anything you can offer would be welcome and helpful.

[hedge_fun]

The Fox and Friends interview did wonders this am........

Hitting $5.

[MissionIR]

AXGN Gets Bullish Review from Seeking Alpha Author

Regenerative medicine company, AxoGen, was recently featured in a Seeking Alpha article in which author Equity Options Guru wrote a continuation of a previous write-up discussing the company’s strong upside based on five key points. To read the article in its entirety, visit http://seekingalpha.com/article/1724602.

AxoGen is focused on peripheral nerve reconstruction and regeneration with an overarching goal to provide treatment for patients suffering from traumatic injuries or who are undergoing surgeries that impact the function of peripheral nerves. The company’s pipeline includes Advance Nerve Graft – the company’s alternative to autografts; AxoGuard Nerve Protector – used to reinforce a coaptation site, wrap a partially severed or compressed nerve, isolate tissue; and the AxoGuard Nerve Connector – a coaptation aid for close approximation of severed nerve ends.

“The target market for these products is the medical community, specifically surgeons. The above technologies can provide a way for surgeons to reconstruct injured nerves without the comorbidities associated with a secondary surgical site,” wrote Equities Options Guru in detailing the company’s technology. “As such, the market potential is immense.”

Further into his positive review of AxoGen, Equity Options Guru details the company’s diverse pipeline of products and technologies, the stock’s recent uplisting to the NASDAQ exchange, significant insider buying, recent coverage by analysts at JMP Securities, and the company’s strong cash balance and revenue growth.

Among other key points, the author also noted that there are two large institutional holders of AxoGen shares, and highlights JMP Securities Outperform rating and $7 price target on the company’s stock, along with reporting information from a recent research note.

In conclusion, Equity Options Guru opines his bullish take on the company.

“Based on the 5 reasons above, it appears that AxoGen is headed for a bright future. With the recent insider buying and positive analyst coverage, investors should begin to take notice of this significantly undervalued company. And with the recent improvement in the company’s financials, AxoGen should begin to gain more traction in the nerve repair market and help investors reap the rewards of an early investment,” stated Equity Options Guru.

For more information visit on AxoGen visit: www.AxoGenInc.com

[MissionIR]

AXGN Gets Bullish Review from Seeking Alpha Author

Regenerative medicine company, AxoGen, was recently featured in a Seeking Alpha article in which author Equity Options Guru wrote a continuation of a previous write-up discussing the company’s strong upside based on five key points. To read the article in its entirety, visit http://seekingalpha.com/article/1724602.

AxoGen is focused on peripheral nerve reconstruction and regeneration with an overarching goal to provide treatment for patients suffering from traumatic injuries or who are undergoing surgeries that impact the function of peripheral nerves. The company’s pipeline includes Advance Nerve Graft – the company’s alternative to autografts; AxoGuard Nerve Protector – used to reinforce a coaptation site, wrap a partially severed or compressed nerve, isolate tissue; and the AxoGuard Nerve Connector – a coaptation aid for close approximation of severed nerve ends.

“The target market for these products is the medical community, specifically surgeons. The above technologies can provide a way for surgeons to reconstruct injured nerves without the comorbidities associated with a secondary surgical site,” wrote Equities Options Guru in detailing the company’s technology. “As such, the market potential is immense.”

Further into his positive review of AxoGen, Equity Options Guru details the company’s diverse pipeline of products and technologies, the stock’s recent uplisting to the NASDAQ exchange, significant insider buying, recent coverage by analysts at JMP Securities, and the company’s strong cash balance and revenue growth.

Among other key points, the author also noted that there are two large institutional holders of AxoGen shares, and highlights JMP Securities Outperform rating and $7 price target on the company’s stock, along with reporting information from a recent research note.

In conclusion, Equity Options Guru opines his bullish take on the company.

“Based on the 5 reasons above, it appears that AxoGen is headed for a bright future. With the recent insider buying and positive analyst coverage, investors should begin to take notice of this significantly undervalued company. And with the recent improvement in the company’s financials, AxoGen should begin to gain more traction in the nerve repair market and help investors reap the rewards of an early investment,” stated Equity Options Guru.

For more information visit on AxoGen visit: www.AxoGenInc.com